• Je něco špatně v tomto záznamu ?

Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats

O. Gawrys, Š. Jíchová, M. Miklovič, Z. Husková, S. Kikerlová, J. Sadowski, P. Kollárová, O. Lenčová-Popelova, L. Hošková, JD. Imig, Y. Mazurova, F. Kolář, V. Melenovský, M. Štěrba, L. Červenka

. 2024 ; 47 (11) : 3126-3146. [pub] 20240909

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003668
E-zdroje Online Plný text

NLK ProQuest Central od 2015-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2015-01-01 do Před 1 rokem

Odkazy

PubMed 39245782
DOI 10.1038/s41440-024-01865-7
Knihovny.cz E-zdroje

All anthracyclines, including doxorubicin (DOXO), the most common and still indispensable drug, exhibit cardiotoxicity with inherent risk of irreversible cardiomyopathy leading to heart failure with reduced ejection fraction (HFrEF). Current pharmacological strategies are clearly less effective for this type of HFrEF, hence an urgent need for new therapeutic approaches. The prerequisite for success is thorough understanding of pathophysiology of this HFrEF form, which requires an appropriate animal model of the disease. The aim of this study was to comprehensively characterise a novel model of HF with cardiorenal syndrome, i.e. DOXO-induced HFrEF with nephrotic syndrome, in which DOXO was administered to Ren-2 transgenic rats (TGR) via five intravenous injections in a cumulative dose of 10 mg/kg of body weight (BW). Our analysis included survival, echocardiography, as well as histological examination of the heart and kidneys, blood pressure, but also a broad spectrum of biomarkers to evaluate cardiac remodelling, fibrosis, apoptosis, oxidative stress and more. We have shown that the new model adequately mimics the cardiac remodelling described as "eccentric chamber atrophy" and myocardial damage typical for DOXO-related cardiotoxicity, without major damage of the peritoneum, lungs and liver. This pattern corresponds well to a clinical situation of cancer patients receiving anthracyclines, where HF develops with some delay after the anticancer therapy. Therefore, this study may serve as a comprehensive reference for all types of research on DOXO-related cardiotoxicity, proving especially useful in the search for new therapeutic strategies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003668
003      
CZ-PrNML
005      
20250206104610.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41440-024-01865-7 $2 doi
035    __
$a (PubMed)39245782
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gawrys, Olga $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats / $c O. Gawrys, Š. Jíchová, M. Miklovič, Z. Husková, S. Kikerlová, J. Sadowski, P. Kollárová, O. Lenčová-Popelova, L. Hošková, JD. Imig, Y. Mazurova, F. Kolář, V. Melenovský, M. Štěrba, L. Červenka
520    9_
$a All anthracyclines, including doxorubicin (DOXO), the most common and still indispensable drug, exhibit cardiotoxicity with inherent risk of irreversible cardiomyopathy leading to heart failure with reduced ejection fraction (HFrEF). Current pharmacological strategies are clearly less effective for this type of HFrEF, hence an urgent need for new therapeutic approaches. The prerequisite for success is thorough understanding of pathophysiology of this HFrEF form, which requires an appropriate animal model of the disease. The aim of this study was to comprehensively characterise a novel model of HF with cardiorenal syndrome, i.e. DOXO-induced HFrEF with nephrotic syndrome, in which DOXO was administered to Ren-2 transgenic rats (TGR) via five intravenous injections in a cumulative dose of 10 mg/kg of body weight (BW). Our analysis included survival, echocardiography, as well as histological examination of the heart and kidneys, blood pressure, but also a broad spectrum of biomarkers to evaluate cardiac remodelling, fibrosis, apoptosis, oxidative stress and more. We have shown that the new model adequately mimics the cardiac remodelling described as "eccentric chamber atrophy" and myocardial damage typical for DOXO-related cardiotoxicity, without major damage of the peritoneum, lungs and liver. This pattern corresponds well to a clinical situation of cancer patients receiving anthracyclines, where HF develops with some delay after the anticancer therapy. Therefore, this study may serve as a comprehensive reference for all types of research on DOXO-related cardiotoxicity, proving especially useful in the search for new therapeutic strategies.
650    _2
$a zvířata $7 D000818
650    12
$a doxorubicin $x škodlivé účinky $7 D004317
650    12
$a srdeční selhání $x chemicky indukované $x patofyziologie $7 D006333
650    12
$a potkani transgenní $7 D055647
650    12
$a nefrotický syndrom $x chemicky indukované $x farmakoterapie $x patofyziologie $7 D009404
650    _2
$a krysa rodu Rattus $7 D051381
650    12
$a modely nemocí na zvířatech $7 D004195
650    12
$a tepový objem $x účinky léků $7 D013318
650    _2
$a protinádorová antibiotika $x škodlivé účinky $7 D000903
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a ledviny $x účinky léků $x patofyziologie $7 D007668
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Miklovič, Matúš $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Husková, Zuzana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kikerlová, Soňa $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Sadowski, Janusz $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kollárová, Petra $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Lenčová-Popelova, Olga $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Hošková, Lenka $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Imig, John D $u Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
700    1_
$a Mazurova, Yvona $u Department of Histology and Embryology, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Kolář, František $u Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Štěrba, Martin $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. luce@ikem.cz $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic. luce@ikem.cz
773    0_
$w MED00006041 $t Hypertension research $x 1348-4214 $g Roč. 47, č. 11 (2024), s. 3126-3146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39245782 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104606 $b ABA008
999    __
$a ok $b bmc $g 2263430 $s 1239675
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 47 $c 11 $d 3126-3146 $e 20240909 $i 1348-4214 $m Hypertension research $n Hypertens Res $x MED00006041
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace